AbbVie Inc. 2012 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2012, for AbbVie Inc. The filing represents the final year of AbbVie's operations as a subsidiary of Abbott Laboratories prior to its separation. On January 1, 2013, AbbVie became an independent, publicly traded company following a distribution of 100% of its common stock to Abbott shareholders. AbbVie operates as a global, research-based biopharmaceutical company with one business segment: pharmaceutical products. Its portfolio includes treatments for rheumatoid arthritis, psoriasis, Crohn's disease, HIV, and metabolic disorders.
Key Financial Metrics
| Metric (in millions) | 2012 | 2011 | 2010 |
|---|---|---|---|
| Net Sales | $18,380 | $17,444 | $15,638 |
| Net Earnings | $5,275 | $3,433 | $4,178 |
| Earnings Per Share (Basic & Diluted) | $3.35 | $2.18 | $2.65 |
| Gross Margin | $13,872 (75% of sales) | $12,805 (73% of sales) | $11,345 (73% of sales) |
| Operating Earnings | $5,817 | $3,620 | $4,717 |
| Cash Flows from Operating Activities | $6,345 | $6,247 | $4,976 |
| Long-Term Debt | $14,652 | $48 | $52 |
| Total Assets | $27,008 | $19,521 | $21,135 |
Product Performance (2012 Sales): HUMIRA generated $9.3 billion (approx. 50% of total sales). Other key products include AndroGel ($1.2 billion), TriCor/TRILIPIX ($1.1 billion), Kaletra ($1.0 billion), and Niaspan ($911 million).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% to $18.38 billion, driven primarily by a 17% increase in HUMIRA sales. This growth was partially offset by unfavorable foreign currency impacts and the entry of generic competition for TriCor in late 2012.
- Debt Structure: Long-term debt increased significantly from $48 million in 2011 to $14.65 billion in 2012. This reflects the issuance of $14.7 billion in senior notes and $1.0 billion in commercial paper in November and December 2012 to fund the separation from Abbott and provide liquidity for the new independent entity.
- Profitability: Net earnings rose 54% to $5.275 billion. This increase was aided by a lower effective tax rate (7.9% in 2012 vs. 6.4% in 2011) due to favorable tax resolutions, and a reduction in litigation charges related to the Depakote investigation ($100 million in 2012 vs. $1.5 billion in 2011).
- Product Declines: Sales for the lipid franchise (TriCor, TRILIPIX, Niaspan) declined 14% due to generic competition and market softness. Kaletra sales declined 13% due to competitive pressures.
Guidance, Outlook, and Risks
- Outlook: Management forecasts low double-digit growth for worldwide HUMIRA sales in 2013. However, the combined lipid franchise sales are expected to drop to less than $1.0 billion in 2013 due to anticipated generic competition for Niaspan and TRILIPIX.
- Dividends: AbbVie expects to pay a regular cash dividend at an annual rate of $1.60 per share, commencing with a quarterly payment in February 2013.
- Capital Allocation: A $1.5 billion stock repurchase program was announced in February 2013.
- Key Risks:
- Patent Expiration: The U.S. patent for HUMIRA (adalimumab) is expected to expire in December 2016, with EU patents expiring in 2018. The company faces potential competition from biosimilars.
- Generic Competition: Immediate and near-term generic competition for TriCor, Niaspan, and TRILIPIX poses a significant revenue risk.
- Regulatory & Legal: AbbVie is subject to a Corporate Integrity Agreement (CIA) and probation related to the Depakote settlement. Non-compliance could result in exclusion from federal health care programs.
- Separation Costs: The company faces increased operating costs as it transitions from Abbott's infrastructure to independent operations, including IT, back-office functions, and corporate services.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to service the new $14.7 billion debt load, particularly given the expectation of approximately $300 million in net interest expense for 2013.
- HUMIRA Dependency: Assess the concentration risk given that HUMIRA accounts for approximately 50% of total sales and the timeline for patent expiration (2016/2018).
- Generic Impact: Monitor the actual sales erosion in the lipid franchise (TriCor, Niaspan, TRILIPIX) as generic competition fully materializes in 2013.
- Separation Costs: Review future financial statements for the impact of "stand-alone" operating costs, which are expected to be higher than the allocated costs reflected in the 2012 historical data.
- Legal Compliance: Confirm ongoing compliance with the Corporate Integrity Agreement and the terms of the Depakote settlement to avoid penalties or exclusion from Medicare/Medicaid.